Loading
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.
Latest quote
¥135
−¥5.00 · -3.57%
Regular session · JST · Market data may be delayed.
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.
Day range
Current ¥135
52-week range
Current ¥135
Regular session · JST · Market data may be delayed.
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.
Day range
Current ¥135
52-week range
Current ¥135
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.23B JPY | 2.98B JPY | 2.43B JPY | 2.95B JPY | 2.23B JPY |
| Cost of goods sold | 1.22B JPY | 1.35B JPY | 1.32B JPY | 1.83B JPY | 1.45B JPY |
| Gross profit | 1.01B JPY | 1.63B JPY | 1.1B JPY | 1.13B JPY | 785.42M JPY |
| Research and development | 627.17M JPY | 536.79M JPY | 384.95M JPY | 501.51M JPY | 535.29M JPY |
| Selling, general, and administrative | 1.25B JPY | 1.22B JPY | 1.13B JPY | 982.41M JPY | 897.26M JPY |
| Operating expenses | 1.87B JPY | 1.76B JPY | 1.51B JPY | 1.48B JPY | 1.43B JPY |
| Interest income | 87.8M JPY | 67.44M JPY | 51.19M JPY | 43.47M JPY | 9.18M JPY |
| Interest expense | — | — | — | 80K JPY | 342K JPY |
| Depreciation and amortization | 74.96M JPY | 50.71M JPY | 37.11M JPY | 48.99M JPY | 59.75M JPY |
| Operating income | −860.06M JPY | −130.41M JPY | −409.29M JPY | −356.22M JPY | −647.13M JPY |
| Net income | −591.69M JPY | 103.25M JPY | −31.42M JPY | −305.31M JPY | −575.1M JPY |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
